<DOC>
	<DOCNO>NCT01645787</DOCNO>
	<brief_summary>The purpose study ass whether 4-AP ( Dalfampridine-ER , Ampyra ) improve walk ability endurance adult patient Spinal muscular atrophy ( SMA ) Type 3 compare placebo whether duration treatment affect outcome .</brief_summary>
	<brief_title>Short Long Term Treatment With 4-AP Ambulatory SMA Patients</brief_title>
	<detailed_description>Spinal muscular atrophy ( SMA ) genetically determine neuromuscular disorder result muscle weakness impair functional mobility . Fatigue common symptom SMA resultant impact physical function quality life however precise mechanism unknown . At present treatment SMA . There evidence 4-AP improves function SMA animal model . In patient multiple sclerosis , 4-AP find improve walk ability diminish fatigue . The purpose study determine whether treatment 4-AP associated increase walk speed endurance compare placebo whether duration treatment affect outcome . The study comprise short term treatment trial participant treat 2 week 4-AP placebo random sequence follow long treatment trial 6 week patient also treat placebo 4 AP . The primary outcome measure clinical study six minute walk test ( 6MWT ) , document valid sensitive instrument identify fatigue among ambulatory SMA patient . We also assess effect 4-AP muscle nerve electrical function via electromyography ( EMG ) short term trial . Results study may provide support large clinical trial .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>1 . Aged 18 50 year time enrollment 2 . Have genetically confirm SMA 3 ( homozygous absence SMN1 exon 7 ) 3 . Ability walk least 25 meter without assistance 4 . Be free major orthopedic deformity ( i.e . scoliosis , contracture ) 5 . Normal Cystatin C clearance ( &gt; 80 ml/min ) 1 . Patients history seizures 2 . Patients renal impairment 3 . Inability comply study procedures 4 . Unstable medical illness 5 . Any ventilatory assistance 6 . Taking experimental medication SMA protocol 7 . Pregnancy lactation 8 . Menstruating woman , sterilize use effective birth control 9 . Planning undergo scoliosis surgery within next 10 month 10 . Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>4-aminopyridine</keyword>
	<keyword>dalfampridine</keyword>
	<keyword>Ampyra</keyword>
</DOC>